SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

OBI Phase III trial shows 40.5% fewer 30-day surgical site infections

OBI’s LANTERN Phase III study met its primary endpoint, with a 40.5% reduction in 30-day surgical site infections after adding nasal photodisinfection to standard care. The report says analyses supported the result and that the intervention showed a strong safety profile.

OBI

The LANTERN Phase III study met its primary endpoint, with nasal photodisinfection added to standard care reducing 30-day surgical site infections by 40.5%. The result was supported by both Bayesian and frequentist analyses. The intervention also showed a strong safety profile and broad-spectrum eff…

Related stories